CALY-002

Indicaton

Celiac Disease, Eosinophilic Esophagitis, Dermatology

Therapeutic indications

Type of product

Antibody

Table

Phase

Phase I started
Partnering status

Not partnered

You may also be interested in

OligoPhore / SemaPhore / CycloPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, linear or circular mRNA and other RNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

AUP-16 (AUP1602-C)

AUP-16 multi-targeting therapy for chronic wounds (Diabetic Foot Ulcers...) shows 50% improvement vs placebo in Phase-2 RCT

Phase II completed

Cadazolid

Crohn's disease

Phase II started